Suppr超能文献

用于诱导抗HIV广泛中和抗体的病毒载体

Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV.

作者信息

Wilmschen Sarah, Schmitz Joern E, Kimpel Janine

机构信息

Division of Virology, Medical University of Innsbruck, Innsbruck 6020, Austria.

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.

出版信息

Vaccines (Basel). 2019 Sep 19;7(3):119. doi: 10.3390/vaccines7030119.

Abstract

Extensive research on generating an efficient HIV vaccine is ongoing. A major aim of HIV vaccines is the induction of long-lasting, broadly neutralizing antibodies (bnAbs) that can confer sterile immunity for a prolonged period of time. Several strategies have been explored to reach this goal, i.e. protein immunization, DNA, or viral vectors, or a combination thereof. In this review, we give an overview of approaches using viral vectors for the induction of HIV-specific bnAbs. Many pre-clinical studies were performed using various replication-competent and -incompetent vectors. Amongst them, poxviral and adenoviral vectors were the most prevalent ones. In many studies, viral vectors were combined with a DNA prime or a protein boost. However, neutralizing antibodies were mainly induced against the homologous HIV-1 vaccine strain or tier 1 viruses, and in rare cases, against tier 2 viruses, indicating the need for improved antigens and vaccination strategies. Furthermore, we also review next generation Env antigens that are currently being used in protein vaccination approaches and point out how they could be utilized in viral vectors.

摘要

目前正在对研发高效的HIV疫苗进行广泛研究。HIV疫苗的一个主要目标是诱导产生持久的、广泛中和抗体(bnAbs),这种抗体能够在较长时间内提供无菌免疫。为实现这一目标,人们探索了多种策略,即蛋白质免疫、DNA或病毒载体,或它们的组合。在本综述中,我们概述了使用病毒载体诱导HIV特异性bnAbs的方法。许多临床前研究使用了各种具有复制能力和无复制能力的载体。其中,痘病毒载体和腺病毒载体最为普遍。在许多研究中,病毒载体与DNA初免或蛋白质加强免疫相结合。然而,中和抗体主要是针对同源HIV-1疫苗株或1级病毒诱导产生的,在极少数情况下是针对2级病毒诱导产生的,这表明需要改进抗原和疫苗接种策略。此外,我们还综述了目前蛋白质疫苗接种方法中使用的下一代Env抗原,并指出它们如何在病毒载体中得到应用。

相似文献

1
Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV.
Vaccines (Basel). 2019 Sep 19;7(3):119. doi: 10.3390/vaccines7030119.
6
Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs.
J Virol. 2018 Jun 13;92(13). doi: 10.1128/JVI.00369-18. Print 2018 Jul 1.
10
Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.
J Transl Med. 2019 May 24;17(1):175. doi: 10.1186/s12967-019-1924-1.

引用本文的文献

本文引用的文献

2
Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance.
Cell. 2019 May 16;177(5):1153-1171.e28. doi: 10.1016/j.cell.2019.04.012. Epub 2019 May 9.
3
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic.
Nat Med. 2019 Apr;25(4):547-553. doi: 10.1038/s41591-019-0412-8. Epub 2019 Apr 1.
4
Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial.
Lancet HIV. 2019 Apr;6(4):e230-e239. doi: 10.1016/S2352-3018(19)30003-7. Epub 2019 Mar 15.
7
Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers.
Immunity. 2019 Jan 15;50(1):241-252.e6. doi: 10.1016/j.immuni.2018.11.011. Epub 2018 Dec 11.
10
Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers.
Cell Rep. 2018 Sep 18;24(12):3324-3338.e5. doi: 10.1016/j.celrep.2018.08.051.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验